Journal of AIDS & Clinical Research

Junhai Guo

Publications

• Research Article
  TRANxITION 144 Week Results: Switching Virologically Stable HIV Patients from Immediate-release Nevirapine (NVP IR) to Extended-Release NVP (XR)
  Author(s): Keikawus Arasteh, Murray Drulak, Junhai Guo, Jean-Michel Livrozet, Chloe Orkin, Ann-Marie Quinson and Douglas WardKeikawus Arasteh, Murray Drulak, Junhai Guo, Jean-Michel Livrozet, Chloe Orkin, Ann-Marie Quinson and Douglas Ward
  
  Purpose: TRANxITION compared efficacy and safety of switching virologically suppressed HIV-1 infected patients from nevirapine (NVP) immediate-release (IR) (200 mg twice-daily) to NVP extended-release (XR) (400 mg oncedaily). Methods: TRANxITION was an open-label, parallel-group, non-inferiority clinical trial where adult patients with undetectable viral loads, receiving NVP IR plus a fixed-dose NRTI combination, were randomized (2:1) to NVP XR or IR. After week 48, patients initially randomized to IR were allowed to switch to XR. Summary of results: At week 48, proportions of patients with virologic response (LLOQ=50 copies/mL TaqMan, FAS) were 88.5% (131/148) in the IR arm, and 88.8% (262/295) in the XR arm, observed difference of 0.3% (95% CI -6.1, 6.7). DAIDS grade 3/4 adverse events were similar in the XR and IR arms at week 48: 6.4% (19/295) vs. 6.1% (9/148). Aft.. Read More»
  DOI: 10.4172/2155-6113.1000292

  Abstract PDF